Eyenuk Revenue and Competitors

Location

#1886

Growjo Ranking

Estimated Revenue & Valuation

  • Eyenuk's estimated annual revenue is currently $10.8M per year.(i)
  • Eyenuk's estimated revenue per employee is $415,115

Employee Data

  • Eyenuk has 26 Employees.(i)
  • Eyenuk grew their employee count by -26% last year.

Eyenuk's People

NameTitleEmail/Phone
1
CEO and FounderReveal Email/Phone
2
CEOReveal Email/Phone
3
Head EngineeringReveal Email/Phone
4
Head Research And DevelopmentReveal Email/Phone
5
Head Product ManagementReveal Email/Phone
6
Head Clinical DevelopmentReveal Email/Phone
7
Head Marketing and Sales OperationsReveal Email/Phone
8
Head Product and Customer SuccessReveal Email/Phone
9
Chief Commercial OfficerReveal Email/Phone
10
Director Sales, US & CanadaReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$20.3M7920%N/AN/A
#2
$8.5M3111%N/AN/A
#3
$4.5M13-13%N/AN/A
#4
$8M25-4%N/AN/A
#5
$5.3M16-6%N/AN/A
#6
$54.2M163-8%N/AN/A
#7
$12M55-17%$63.2MN/A
#8
$10M30-9%N/AN/A
#9
$30.1M12022%N/AN/A
#10
$14.1M43-7%N/AN/A
Add Company

What Is Eyenuk?

Eyenuk, Inc. is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening for autonomous disease detection and AI Predictive Biomarkersâ„¢ for risk assessment and disease surveillance. Eyenuk's first product, the EyeArt AI Eye Screening System, is the most extensively validated AI technology for autonomous detection of diabetic retinopathy. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk and Alzheimer's disease.

keywords:N/A

N/A

Total Funding

26

Number of Employees

$10.8M

Revenue (est)

-26%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.5M26-10%N/A
#2
$10.7M26-45%N/A
#3
$6.7M2613%N/A
#4
$2.5M26N/AN/A
#5
$2.6M26N/AN/A